Gentamicin combination treatment is associated with lower mortality in patients with invasive listeriosis: a retrospective analysis
Open Access
- 4 July 2024
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 52 (4) , 1601-1606
Abstract
Purpose: Listeria monocytogenes causes severe bacterial infections with the highest mortality rate among foodborne pathogens in Europe. Combination treatment with ampicillin and gentamicin is recommended for invasive manifestations. However, evidence to support this treatment approach remains limited due to a lack of randomised controlled trials. To explore this critical issue further, we conducted this retrospective, single-center study. Methods: We identified all patients hospitalized with invasive listeriosis at the University Medical Center Hamburg-Eppendorf between 2009 and 2020 and analyzed the effect of gentamicin combination treatment versus monotherapy on 90-day mortality. Results: In total, 36 patients with invasive listeriosis were included, of which 21 patients received gentamicin combination treatment and 15 received monotherapy. The mean age-adjusted Charlson Comorbidity Index (aaCCI) value was lower in the gentamicin combination treatment group (5.4 vs. 7.4). Neurolisteriosis was more common in the gentamicin group (81% vs. 20%). The 90-day mortality was with significantly lower in the gentamicin combination treatment group (10%) compared to the monotherapy group (60%). Multivariable cox regression analysis, adjusted for a propensity score computed based on neurolisteriosis, aaCCI and sex, revealed a significantly reduced hazard ratio of 0.07 (95% CI: 0.01–0.53, p = 0.01) for 90-day mortality for the gentamicin combination treatment. Conclusion: This retrospective study highlights the benefit of gentamicin combination treatment in reducing the 90-day mortality rate among patients with invasive listeriosis. The high prevalence of monotherapy in this study cohort raises concerns about the adequacy of antibiotic therapy in clinical practice.Keywords
Funding Information
- Universitätsklinikum Hamburg-Eppendorf (UKE)
This publication has 11 references indexed in Scilit:
- Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiotaFrontiers in Pharmacology, 2023
- Risk factors associated with early mortality after recovery from severe listeriosis: a multicentre 17-year longitudinal studyInfection, 2022
- Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010–2018European Journal of Clinical Pharmacology, 2021
- Mortality risk factors for listeriosis – A 10 year review of non-pregnancy associated cases in England 2006–2015Journal of Infection, 2019
- Use of proton pump inhibitors and the risk of listeriosis. A nationwide registry-based case-control studyClinical Infectious Diseases, 2016
- The global burden of listeriosis: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2014
- Three-year multicenter surveillance of community-acquired listeria monocytogenes meningitis in adultsBMC Infectious Diseases, 2010
- Therapeutic optionsFEMS Immunology & Medical Microbiology, 2003
- Incidence of and Significant Risk Factors for Aminoglycoside-Associated Nephrotoxicity in Patients Dosed by Using Individualized Pharmacokinetic MonitoringThe Journal of Infectious Diseases, 1993
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987